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DETERMINING THE ROLE OF TUMOR-DERIVED LEUKEMIA INHIBITORY 
FACTOR IN CANCER CACHEXIA USING A GENETIC APPROACH 
JOHN DANIEL GANEY 
ABSTRACT 
 Cachexia is a multifactorial metabolic wasting syndrome that affects a large 
percentage of cancer patients and results in the involuntary loss of skeletal muscle and 
adipose tissue. The consequences of this condition include metabolic imbalances and 
fatigue, which are strongly associated with poor prognosis. While the specific mechanism 
for skeletal muscle wasting is still undefined, LIF secreted by C26 colon carcinoma cells 
has recently be found to induce atrophy in treated myotubes. The purpose of this study is 
to determine the necessity of LIF for inducing atrophy in mouse myotubes by producing a 
knockout of Lif in C26 cells using CRISPR-Cas9. Media was collected from these cells 
and used to treat myotubes. Measurements of myotube diameters were made and atrophy 
was compared between myotubes that received medium from C26 and C26Lif-/-	cells. A 
dosage of recombinant mouse LIF was also added to LIF-deficient medium in order to 
determine if LIF alone was sufficient to induce atrophy. At study endpoint, myotubes that 
were treated with media taken from C26 cells showed significant signs of atrophy 
compared to myotubes that were treated C26Lif-/-	media. LIF was also shown to be 
sufficient to induce myotube atrophy on its own, with atrophy being rescued in myotubes 
that received a dosage of LIF added to C26Lif-/- media. These results demonstrate that LIF 
is required for atrophy to be induced in mouse myotubes treated with media taken from 
cancer cells, and can do so independent of other secreted factors. 
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CHAPTER 1: STUDY RATIONALE 
I. Introduction 
Cancer-associated cachexia is a multifactorial condition that affects more than 
30% of cancer patients and is characterized by inflammation and involuntary loss of fat 
and skeletal muscle that is not reversible by increasing caloric intake. (2, 7, 6, 30). 
Skeletal muscle atrophy is responsible for muscle weakness, fatigue, metabolic 
imbalances, inability to fight off infections, an intolerance to anticancer therapy, and even 
death (5, 7, 23). In addition, because of the deleterious consequences of skeletal muscle 
loss, cancer-associated cachexia is an important factor in determining patient prognosis 
(17).  
 
II. Proposed Cachexia Mechanisms 
Previous studies have attempted to determine the mechanism of skeletal muscle 
atrophy caused by cancer cachexia. Inflammation is pervasive in mouse and human 
cancer-cachexia (24, 30). The mediators of atrophy are thought to involve the release of 
proinflammatory cytokines or chemokines from cancerous cells. These and other secreted 
factors induce changes in gene expression that affect metabolism and cause loss of 
skeletal muscle mass (8, 20, 25). Several signaling pathways and transcription factors 
have been linked to muscle atrophy, such as JAK/STAT (3, 26), FOXO (14), and ERK 
(24, 26).  
An in-depth investigation of these pathways as mediators of muscle atrophy was 
performed in mouse C2C12 muscle cells.  Cultured and differentiated muscle cells, 
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known as myotubes, were treated with secretions from mouse C26 colon carcinoma cells, 
the most common cancer cell used to study cancer cachexia in mice. Treatment of 
myotubes with C26 cancer cell secretions revealed that only JAK/STAT and ERK 
signaling pathways, but not other pathways (such as Ap-1, C/EBP, FOXO, or NF-kB), 
were activated in myotubes. By testing all of the upstream ligands known to activate 
STAT signaling, one of these cytokines, Leukemia Inhibitory Factor (LIF), was to found 
responsible for STAT3 activation. Blocking antibodies against mouse LIF were used and 
found to completely inhibit STAT activation and myotube atrophy in response to 
treatment with C26 cancer cell secretions (26).  
 
III. Leukemia Inhibitory Factor  
A. LIF Signaling Pathways 
 
LIF is a pleotropic cytokine that can activate signaling pathways and transcription 
factors that cause inflammation (21). As a member of the interleukin-6 family of 
cytokines, LIF signals through the Glycoprotein 130 (gp130) family of ubiquitously 
expressed transmembrane cytokine receptors. It does this by first binding to its specific 
type of receptor called LIF Receptor a (LIFRa). After binding to LIFRa, the receptor 
forms a heterodimer with the gp130 receptor (29, 31) which induces the phosphorylation 
of tyrosine on the cytoplasmic tail. This heterodimer association and subsequent 
phosphorylation activates JAK family kinases, allowing them to phosphorylate 
downstream targets (9). Activation of this enzyme triggers successive tyrosine 
phosphorylations that activate the signal pathways STAT and MAPK (4, 10), all of which 
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result in a specific of downstream effects, including gene expression. 
 
B. LIF Biological Activity  
 
The biological activity of LIF is diverse and has been linked to several functions 
including the regulation of cell pluripotency (22) and development (28). Other studies 
have shown that LIF inhibits myogenesis in muscle cells by preventing differentiation (1, 
13). Earlier work done in the 1990s showed a strong correlation between several types of 
tumor-bearing mice with cachexia and serum LIF (11, 15, 19). LIF is a known inhibitor 
of lipoprotein lipase in adipocytes, which leads to a loss of body fat. Taken together, 
these data made LIF a prime candidate as a triggering factor for skeletal muscle wasting. 
However, these studies were not followed-up, perhaps because of the technical 
limitations of the time.  
 
IV. Specific Aims and Objectives 
The purpose of the present study was to test the necessity of LIF for inducing 
atrophy in C2C12 mouse myoblasts using a genetic approach to knock out the LIF gene 
in C26 tumor cells. The use of C2C12 myotubes in cell culture is an effective model to 
study cachexia because it allows for direct study of tumor secreted factors without the 
interference from other ligands or biological factors present in vivo (12, 26). To study the 
necessity of LIF in cachexia, a bi-allelic knockout of the Lif gene in C26 cells was 
created using CRISPR-Cas9, preventing the production of the LIF by C26 tumor cells 
and allowing for the creation of conditioned medium that was deficient in LIF (C26Lif-/-	
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CM). Media was collected from C26Lif-/-	cancer cells and from C26 cells and was used to 
treat myotubes. Diameters of the myotubes were then compared to determine if the lack 
of LIF in the cancer cell CM prevented atrophy. Further, I determined whether the 
addition of LIF to C26Lif-/-	CM was sufficient to rescue atrophy in myotubes.   
Another question I investigated was whether myotube atrophy due to treatment 
with C26 CM was capable of recovery when myotubes were no longer exposed to media 
containing tumor-derived factors. Last, I tested the effect of serum in C26 CM on 
myotube atrophy, because LIF and other cytokine levels were lower in medium collected 
from C26Lif-/-	cells.  
Overall, myotubes treated with C26Lif-/-	CM did not atrophy and grew at the same 
rate as control myotubes, indicating LIF is required for myotube atrophy in response to 
secretions from C26 cells. Myotubes incubated in C26Lif-/- CM that received a bolus 
addition of LIF demonstrated atrophy when compared to cells treated with C26Lif-/-	CM 
that did not receive LIF. Constant exposure to LIF was also necessary for atrophy to be 
maintained because replacing C26 CM with normal differentiation medium (DM) in 
cultures where myotubes had atrophied rescued them from a cachectic phenotype. That 
is, myotubes returned to a size comparable to myotubes that had received DM alone. I 
found that the use of serum to make C26 CM had no effect on atrophy because myotubes 
treated with CM taken from serum-deficient cultures was still able to induce atrophy. 
Taken together, these data indicate that LIF secreted by mouse C26 colon 
adenocarcinoma cells is required for all of the myotube atrophy. 
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CHAPTER 2: METHODS 
I. Genetic Knockout of the Lif gene in C26 tumor cells  
C26 cells were submitted to Applied Biological Materials (ABM, Vancouver, 
CA) where the Lif gene was knocked out using ABM’s method of lentivirus delivered 
CRISPR-Cas9. The mouse Lif gene was targeted in a unique part of the second exon and 
a bi-allelic knockout was produced. The DNA sequencing results provided by ABM 
verified the two mutant alleles in the C26 knockout clone. The mutant alleles each had 
sequence deletions, the first one was a 2 bp and the other was 4 bp in the target site in 
exon 2. This produced a frame shift at the 47th and 46th amino acid, respectively, of the 
full-length mouse LIF protein (the 24th and 23rd amino acid of the mature secreted form 
of LIF). We analyzed the sequences against the known mouse Lif gene data online using 
MacVector, in order to predict the sequence of the shorter mutant peptides made in the 
C26Lif-/-	cells 
 
II. C2C12 Cell Culture 
C2C12 myoblasts (obtained from American Type Culture Collection, Manassas, 
VA) were grown and maintained in growth media consisting of high glucose Dulbecco’s 
Modified Eagle Medium (DMEM) with 1.2% penicillin-streptomycin (Invitrogen) and L-
Glutamine (Invitrogen), and 10% fetal bovine serum (Invitrogen). This growth medium 
(GM) is standard media for proliferating cells. These cells were cultured in an incubator 
at 37°C and 5% CO2 until they were confluent enough to differentiate. Myotubes were 
then passed into 6-well plates containing GM, with 3 independent wells per experimental 
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group. After 24 hours, GM was removed and replaced with differentiation medium (DM) 
consisting of high glucose Dulbecco’s Modified Eagle Medium (DMEM) with 1.2% 
penicillin-streptomycin (Invitrogen) and L-Glutamine (Invitrogen), and 2% Horse Serum 
(Invitrogen), and incubated at 37°C in a 5% CO2 environment and allowed to 
differentiate into myotubes for four days. The DM used is standard for myotube 
differentiation in culture. Reduction of serum from 10% fetal bovine serum to 2% horse 
serum induces myoblast to fuse and differentiate (27). 
 
III. Conditioned Medium 
Conditioned Medium (CM) was made using both C26 and C26Lif-/-	
adenocarcinoma cells incubated at 37°C with 5% CO2. The cells were cultured in GM at 
37°C and 5% CO2 and the media was removed when the cells reached 90% confluency. 
At this point they were washed twice with sterile PBS and then three times with DMEM 
containing 1.2% penicillin-streptomycin (Invitrogen) and L-Glutamine (Invitrogen), and 
no serum. The cells were then incubated in DM for 24 hours. Next, the media was 
collected into a 50 mL Falcon tube and centrifuged at 4500 RPM for 15 minutes at 4°C. 
The media was aliquoted and stored at -80°C. The medium used to treat the cultured 
myotubes during experiments contained 33% CM and 67% DM, with control myotubes 
receiving 100% DM. For one experiment recombinant mouse LIF (R&D Systems) was 
added to C26Lif-/-	CM and DM using previously measured levels of LIF in C26 CM (1500 
pg/ml). 
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IV. Immunocytochemistry 
Myotubes were fixed in 1% formaldehyde solution for 20 minutes, and then 
permeabilized with 1% Triton X-100 for another 20 minutes. They were then washed 
with PBS- 0.5% Tween and blocked in 20% Odyssey Blocker in PBS. Myotubes were 
then incubated in a solution containing mouse monoclonal myosin antibody for 2 hours 
(MF-20, Development Studies Hybridoma Bank, Iowa City, Iowa). The cells were then 
washed again with PBS-Tween and incubated with a secondary antibody, goat anti-
mouse fluorescein-conjugated Alexa Fluor 488 (Life Technologies). The resulting 
fluorescence of myotubes was visualized by using a FITC-HYQ filter on a Nikon TS-
5000 inverted microscope. 
 
V. Myotube Measurements in vitro  
Treatment of myotubes that had been differentiated for four days began at Day 0 
and proceeded for three days (six days in the case of the recovery experiment). Myotubes 
were photographed every day using phase light microscopy at 20x magnification with a 
Nikon TS-500 inverted fluorescent microscope. Images were taken at the 0, 24, 48, and 
72-hour time points (up to 144 hours for the recovery experiment), with at least 7 pictures 
taken per well at random locations, using Spot RT camera and Spot Software (Diagnostic 
Instruments). Fresh media was replaced at each time-point. At least 100 myotube 
diameters per group were made using MetaMorph Imaging software (Universal Imaging) 
by tracing an area of a box 100 µm in length along the edge myotubes in order to 
measure the average diameter.   
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CHAPTER 3: RESULTS 
I. C26Lif-/- Media Does Not Induce Atrophy in C2C12 Myotubes.  
To test whether LIF was necessary to induce atrophy, differentiated myotubes 
were treated with either C26 CM or CM taken from C26 cells that had their Lif gene 
knocked-out using CRISPR (i.e., C26Lif-/- CM). Phase images were taken every 24 hours 
to observe the growth trend (0, 24, 48, 72 hours). Imaging software was used to measure 
the diameters of myotubes at each time point (Fig. 1A). After 72 hours of treatment, cells 
that were incubated in C26 CM had myotube diameters 15% smaller than control 
myotubes in DM, while cells that were treated with C26Lif-/- CM did not atrophy. 
Immunocytochemistry was performed on the myotubes at 72 hours. Fluorescent imaging 
allows for clearer visualization of myotubes treated with C26 CM or DM. Analysis of 
these fluorescent myotube images confirmed the change measured on the phase images 
(Fig 1B, C). Compared to the control group, C26Lif-/- CM treated myotubes had no 
difference in size, while myotubes cultured in C26 CM had statistically smaller diameters 
and were visibly thinner. 
 
II. Addition of LIF to C26Lif-/- CM Rescued Atrophy in C2C12 myotubes  
C2C12 myotube cultures were incubated in either C26 CM, C26Lif-/- CM, or DM. 
LIF was added to C26Lif-/- CM and to DM at 1500 pg/mL to give it the same 
concentration of LIF in C26 CM. Addition of LIF to C26Lif-/- CM resulted in a significant 
reduction in myotube diameter compared to myotubes that had only received LIF-
deficient media (Fig. 2A). Thus, myotube atrophy was rescued in C26Lif-/- CM treated 
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myotubes by adding LIF. The addition of LIF alone to DM was enough to cause atrophy 
in myotubes and resulted in diameters comparable to myotubes treated with C26 CM 
(Fig. 2B). Immunocytochemistry was performed on the myotubes at the study end point 
(72 hours). The differences in myotube sizes in experimental groups that received added 
LIF were visually evident (Fig. 2C). 
 
III. Cachectic Myotubes Recover from Atrophy by Removal of C26 CM  
I next tested if exposure to LIF in C26 CM needed to be maintained in order for 
myotubes to atrophy. That is, I tested whether it was possible to reverse myotube atrophy 
if C26 CM treatment was stopped and replaced with DM. Differentiated myotubes were 
treated with C26 CM for 72 hours to induce atrophy, next, C26 CM was replaced with 
DM for another 72 hours. At the 72-hour time point, myotubes treated with C26 CM 
were significantly atrophied when compared to control myotubes (Fig. 3A). After C26 
CM was removed and replaced with DM the size of the myotubes was not different from 
the control groups 24 hours later. Myotubes that were continually treated with C26 CM 
for the full 144-hour time frame were significantly smaller compared to myotubes in 
control and recovery groups.  
Because of the process used during immunocytochemistry this procedure is only 
able to be done at the final time point (Fig. 3A). Measurements of fluorescent images at 
144 hours showed an even more pronounced size difference in the C26 CM treated 
myotubes versus control myotubes compared to measurements made of phase images of 
the same myotubes. Myotubes treated with C26 CM atrophied 20% compared to control 
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myotubes. Rescued myotubes were able to recover and grow to sizes comparable to 
control myotubes (Fig. 3B). Immunocytochemistry emphasized the difference between 
C26 CM treated myotubes, which were visibly smaller compared to control and rescued 
myotubes (Fig. 3C).  
 
IV. Serum in C26 Conditioned Medium Has No Significant Effect on Atrophy  
Myotubes were treated with conditioned media collected from C26 cells and 
C26Lif-/- cells grown in media that did not contain serum. The myotubes that were treated 
with C26 CM atrophied compared to the control group, while myotubes treated with 
C26Lif-/- CM were not statistically different from control myotubes (Fig. 4A). After 
performing immunocytochemistry, the myotubes were photographed and their diameters 
measured at the 72-hour time point. There was no difference in myotube size between 
C26Lif -/- CM treated myotubes and control myotubes. Myotubes treated with C26 CM 
without serum had atrophy (Fig. 4B) comparable to cells that were treated with 
conditioned media containing serum (Fig. 1B). Fluorescent imaging was used in order to 
visualize the difference in diameters of myotubes treated with C26 CM or DM (Fig. 4C). 
ELISA measurements of LIF levels in C26 conditioned medium was performed and 
showed that the absence of serum in C26 cultures resulted LIF levels that were a third of 
what was found in the media of C26 cultures containing serum (Fig. 4D). However, the 
atrophy was not different in cultures with 500 pg/mL versus 1500 pg/mL of LIF (Fig. 1A 
vs. 4A).
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CHAPTER 4: DISCUSSION 
The purpose of this study was to investigate the role of LIF in cancer-associated 
cachexia using a genetic approach. Previous work done in our lab has shown that LIF is 
necessary for the activation of the STAT3 signaling pathway in C2C12 mouse myotubes 
when exposed to secretions from C26 adenocarcinoma cells, as well as being necessary 
for C26 CM-induced myotube atrophy (26). In the present work, a bi-allelic knockout of 
the Lif gene in C26 adenocarcinoma cells was used to create C26Lif-/- conditioned media. I 
used this genetic difference in the C26 cells to test if LIF is required for C2C12 myotube 
atrophy in response to secretions from C26 cancer cells.  
 Cultured C2C12 myotubes did not atrophy when treated with C26Lif-/- CM, 
indicating that LIF is necessary for C26 CM-induced atrophy. These results are supported 
by our lab’s previous work which showed that blocking antibodies against LIF prevents 
myotube atrophy (26). The C26 Lif knockout cells were also used in vivo, and mice 
inoculated with C26Lif-/- cells showed marked attenuation of wasting in bother skeletal 
muscle and adipose tissue, compared to C26 tumor bearing mice (16). Previous reports 
also show mice with LIF-secreting tumors become cachectic (11, 15, 19) but until 
recently, there was no way to link LIF as the causative agent for cachexia.  
Knocking out the Lif gene had an effect on the production of other cytokines 
found in conditioned media. Cytokines such as IP-10 (CXCL10), MCP-1, RANTES, 
MIP-2, MIP1a, MIP-1b, and IL-6 were all measured at much lower levels in C26Lif-/- CM 
than in C26 CM (16). In order to determine whether LIF’s induction of atrophy was not 
dependent on the presence of these other proteins, a bolus dose of LIF was added to 
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C26Lif-/- CM and to DM and used to treat myotubes. Myotubes that received C26Lif-/- CM 
and LIF showed atrophy and were significantly smaller compared to myotubes that 
received C26Lif-/- CM, which grew at a rate that matched control myotubes. Similar results 
were seen when DM was supplemented with LIF and incubated with myotubes. Cells that 
were grown in DM with added LIF showed significant atrophy over the course of 
treatment compared to control myotubes. These findings show that LIF-induced atrophy 
is not dependent on the presence of cytokines that were elevated in C26 CM. This is 
consistent with data showing that direct injection of purified LIF into healthy mice was 
sufficient to induce body fat loss (Metcalf, et al., 1990).  
After showing that LIF is the cytokine responsible for inducing atrophy, I 
investigated whether atrophy could be stopped or reversed by withdrawing the C26 
cancer cell conditioned medium. Removing C26 CM from myotubes and replacing it 
with differentiation media rescued the myotubes from atrophy. That is, when the C26 CM 
was changed to DM, myotube diameter quickly increased. Only 24 hours after the switch 
to DM, myotube size was the same as for control myotubes. These results indicate that 
constant exposure to LIF is necessary for atrophy to be maintained, and the cachectic 
phenotype is capable of being reversed if the stimulus is removed. This suggests that 
reversal of cachexia is possible in vivo if the cachexia-inducing factor is blocked. 
Interestingly, comparison of the in vitro and in vivo models shows that the level of 
LIF found in the serum of cachectic tumor-bearing mice is lower than the concentration 
of LIF in C26 CM used to treat myotubes (12). It was also found that the use of 
Transwell plates to incubate C26 and C2C12 cells together to better simulate 
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physiological conditions resulted in greater atrophy compared to treating myotubes with 
media collected from C26 cells (12).  These findings suggest that the constant exposure 
to lower concentrations of secreted LIF from C26 cells is more important for inducing 
atrophy than a higher concentration of LIF that is delivered in a bolus type of dose.  
I also observed that the use of serum to make the C26 conditioned medium had no 
effect on myotube atrophy. There was no significant difference between diameters of 
myotubes that were incubated in CM without serum compared to those that were 
incubated in CM with serum. Measurement of cytokine levels show that incubation of 
C26 tumor cells in media that does not contain serum results in a lower concentration of 
LIF being secreted when compared to levels of LIF found in C26 cultures containing 
serum (16). However, the concentration of LIF in C26 CM without serum was still 
relatively high (500 pg/mL), and there was no difference in myotube atrophy in C26 CM 
with or without serum, showing that this lower amount of LIF was still sufficient to 
induce atrophy.  
I. Conclusion 
The goal of my thesis was to determine the necessity of Leukemia Inhibitory 
Factor in the atrophy of skeletal muscle caused by cancer cachexia using a genetic 
approach. Here, LIF secreted by C26 adenocarcinoma cells was shown to be the factor 
responsible for causing atrophy in C2C12 mouse myotubes. C26 CM that did not contain 
LIF, did not induce atrophy in C2C12 myotubes, and the addition of LIF to C26Lif-/- CM 
or to differentiation medium was sufficient to cause atrophy. LIF’s effect on myotubes 
was also shown to be reversible, as replacing C26 CM with DM rescued them from 
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atrophy. Although the lack of serum in C26 cell culture results in decreased LIF 
production, it is still secreted at high enough concentrations to induce atrophy in 
myotubes. Using these methods of investigation, LIF was determined to be the causative 
agent for inducing the atrophy of C2C12 mouse myotubes in the C26 adenocarcinoma 
model. Cancer cachexia is a debilitating condition affecting at least 30% of cancer 
patients and is caused by tumor-secreted factors that vary depending on the type of cancer 
cell. Leukemia Inhibitory Factor is the cytokine responsible for this condition in C26 
tumor bearing mice. The use of the tools and techniques in this thesis and our lab’s 
previous work provide a template for identifying cachexia-inducing factors in human 
cancers in order to subsequently set up effective treatments against cachexia in patients. 
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Figure 1:  Diameters of Control (DM), C26 CM, and C26Lif -/- CM Treated 
Myotubes.  
(A) Measurements of C2C12 myotubes made at 0 (Day 4 of differentiation), 24, 48, and 
72 hours of treatment with C26 CM or C26Lif-/- CM. (B) Measurement of fluorescent 
myotubes after immunocytochemistry at 72 h treatment. (C) Representative images of 
fluorescent myotubes from 72 h control, C26 CM, and C26Lif-/- CM treated groups. (*P < 
0.05 significantly different to control value, †P < 0.05 compared to C26 CM value) 
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Figure 2:  Treatment of C2C12 Myotubes with mLIF.  
(A) Measurements C2C12 myotubes made at 0 (Day 4 of differentiation), 24, 48, and 72 
hours of treatment with C26Lif-/- CM or C26Lif-/- CM + LIF. (B) Measurements made at 0 
(day 4), and 24, 48, and 72 hours of treatment with DM or DM + LIF. (C) Representative 
images of fluorescent myotubes from 72 h control, DM + LIF, C26Lif-/- CM, and C26Lif-/- 
CM + LIF treated groups. (*P < 0.05 significantly different to control value, †P < 0.05 
compared to C26 CM value)  
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Figure 3:  Cachectic Myotube Rescue After 72 hours of Treatment with C26 CM. 
(A) Measurements made at 0 (Day 4 of differentiation), 24, 48, 72, 96, 120, and 144 
hours of treatment with C26 CM or DM. Rescue myotubes received CM from 0 to 72 
hours then DM from 72 to 144 hours. (B) Measurement of fluorescent myotubes after 
immunocytochemistry at 144 h treatment. (C) Representative images of fluorescent 
myotubes from 72 h control, C26 CM, and rescue treated groups. (*P < 0.05 significantly 
different to control value, †P < 0.05 compared to C26 CM value) 
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FIGURE 4:  Treatment of C2C12 Myotubes with CM Made without Serum.  
(A) Measurements made at 0 (Day 4 of differentiation), 24, 48, and 72 hours of treatment 
with C26 CM NS (no serum) or C26Lif-/- CM NS (no serum). (B) Measurement of 
fluorescent myotubes after immunocytochemistry at 72 h treatment. (C) Representative 
images of fluorescent myotubes from 72 h control, C26 CM containing no serum, and 
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20 
C26Lif-/- CM containing no serum treated groups. (*P < 0.05 significantly different to 
control value, †P < 0.05 compared to C26 CM value) 
		
21 
BIBLIOGRAPHY 
1. Alter J, Rozentzweig D, and Bengal E. Inhibition of Myoblast Differentiation by 
Tumor Necrosis Factor Alpha is mediated by c-Jun N-Terminal kinase 1 and leukemia 
inhibitory factor. Journal of Biological Chemistry 283(34): 23224-23234, 2008 
2. Argilés JM Cancer cachexia: Understanding the molecular basis. Nature Reviews. 
Cancer 14(11): 754-762, 2014 
3. Bonetto A, Aydogu T, Jin X, Zhang Z, Zhan R, Puzis L, Koniaris LG, and 
Zimmers TA. JAK/STAT3 pathway inhibition blocks skeletal muscle wasting 
downstream of IL-6 and in experimental cancer cachexia. American Journal of 
Physiology-Endocrinology and Metabolism 303: E410-E421, 2012 
4. Burdon T, Stracey C, Chambers I, Nichols J, and Smith A. Suppression of SHP-
2 and ERK Signalling Promotes Self-Renewal of Mouse Embryonic Stem Cells. 
Developmental Biology 210: 30-43, 1999 
5. Cohen S, Nathan J, and Goldberg AL . Muscle wasting in disease: molecular 
mechanisms and promising therapies. Nature Reviews. Drug Discovery 14: 58-74, 2015 
6. Evans WJ. Cachexia: A new definition. Clinical Nutrition 27(6): 793-799, 2008 
7. Fearon K. Definition and classification of cancer cachexia: an international 
consensus. The Lancet Oncology 12(5): 489-495, 2011 
8. Fearon KC, Glass DJ, and Guttridge DC. Cancer Cachexia: Mediators, 
Signlaning, and Metabolic Pathways. Cell Metabolism 16: 153-166, 2012 
9. Heinrich PC, Berhmann I, Muller-Newen G, Schaper F, and Graeve L. 
Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway1. 
Biochemical Journal 334: 297–314, 1998 
10. Hidemasa O, Fujio Y, Kunisada K, Hirota H, Matsui H, Kishimoto T, and 
Yamauchi-Takihara K. Activation of Phosphatidylinositol 3-Kinase through 
Glycoprotein 130 Induces Protein Kinase B and p70 S6 Kinase Phosphorylation in 
Cardiac Myocytes. The Journal of Biological Chemistry 273(16): 9703–9710, 1998 
11. Iseki H, Kajimura N, Ohue C, Tanaka R, Akiyama Y, and Yamaguchi K. 
Cytokine Production in Five Tumor Cell Lines with Activity to Induce Cancer Cachexia 
Syndrome in Nude Mice. Japanese Journal of Cancer Research 86(6): 562–567, 1995 
12. Jackman RW, Floro J, Yoshimine R, Zitin B, Eiampikul M, El-Jack K, Seto 
DN, and Kandarian SC. Continuous Release of Tumor-Derived Factors Improves the 
Modeling of Cachexia in Muscle Cell Culture. Frontiers in Physiology 8(738), 2017 
		
22 
13. Jo C, Kim H, Jo I, Choi I, Jung S, and Kim J. Leukemia Inhbitory Factor blocks 
early differentiation off skeletal muscle cells by activating ERK. Biochimica et 
Biophysica Acta 1743: 187-197, 2005 
14. Judge SM, Wu CL, Beharry AW, Roberts BM, Ferreira LF, Kandarian SC, 
and Judge AR. Genome-wide identification of FoxO-dependent gene networks in 
skeletal muscle during C26 cancer cachexia. BMC Cancer 14: 997, 2014 
15. Kajimura N, Iseki H, Tanaka R, Ohue C, Otsubo K, Gyoutoku M, Sasaki K, 
Akiyama Y, and Yamaguchi K. (1996). Toxohormones responsible for cancer cachexia 
syndrome in nude mice bearing human cancer cell lines. Cancer Chemotherapy and 
Pharmacology 38: 48-52, 1996 
16. Kandarian SC, Nosacka RL, Delitto AE, Judge AR, Judge SM, Ganey JD, and 
Jackman RW. Tumor-derived LIF is a major driver of cancer cachexia and morbidity in 
C26 tumor-bearing mice. Journal of Cachexia, Sarcopenia and Muscle In text, 2018. 
17. Martin L, Birdsell L, MacDonald N, Reiman T, Clandinin MT, McCargar LJ, 
Murphy R, Gosh S, Sawyer MB, and Baracos VE. Cancer Cachexia in the Age of 
Obesity: Skeletal Muscle Depletion Is a Powerful Prognostic Factor, Independent of 
Body Mass Index. Journal of Clinical Oncology 31(12): 1539-1547, 2013 
18. Metcalf D, Nicola N, and Gearing D. Effects of injected leukemia inhibitory factor 
on hematopoietic and other tissues in mice. Blood 76(1): 50-56, 1990 
19. Mori M, Yamaguchi K, Honda S, Nagasaki K, Ueda M, Abe O, and Abe K. 
Cancer Cachexia Syndrome Developed in Nude Mice Bearing Melanoma Cells 
Producing Leukemia-inhibitory Factor1. American Association of Cancer Research 
51(24): 6656-6659, 1991 
20. Mueller TC, Bachmann J, Prokopchuk O, Friess H, and Martignoni ME. 
Molecular pathways leading to loss of skeletal muscle mass in cancer cachexia – can 
findings from animal models be translated to humans? BMC Cancer 16: 75-86, 2016 
21. Nicola NA, and Babon, JJ. Leukemia inhibitory factor (LIF). Cytokine & Growth 
Factor Reviews 26(5): 533-544, 2015 
22. Onishi K, and Zandstra PW. LIF signaling in stem cells and development. 
Development 142: 2230-2236, 2015 
23. Penet MF, and Bhujwalla ZM. Cancer Cachexia, Recent Advances, and Future 
Directions. The Journal of Cancer 21(2): 117-122, 2015 
		
23 
24. Penna F, Costamagna D, Fanzani A, Bonelli G, Baccino FM, and Costellia P. 
Muscle wasting and imparied myogenesis in tumor bearing mice are prevented by ERK 
inhibition. PLoS ONE 5: e13604, 2010 
25. Petruzzelli M, and Wagner EF. Mechanisms of metabolic dysfunction in cancer-
associated cachexia. Genes & Development 30(5): 489-501, 2016 
26. Seto D, Kandarian SC, and Jackman RW. A Key Role for Leukemia Inhibitory 
Factor in C26 Cancer Cachexia. Journal of Biological Chemistry 290(32): 19976-19986, 
2015 
27. Silberstein L, Webster SG, Travis M, and Blau HM. Developmental progression 
of myosin gene expression in cultured muscle cells. Cell 46: 1075-1081, 1986 
28. Simamura E, Shimada H, Higashi N, Uchishiba M, Otani H, and Hatta T. 
Maternal Leukemia Inhibitory Factor (LIF) Promotes Fetal Neurogenesis via a LIF-
ACTH-LIF Signaling Relay Pathway. Endocrinology 151(4): 1853-1862, 2010 
29. Skiniotis G, Lupardus P, Martick M, Walz T, and Garcia K. Structural 
organization of a full-length gp130/LIF-R cytokine receptor transmembrane complex. 
Molecular Cell 31(5): 737–748, 2008 
30. Tisdale MJ. Mechanisms of Cancer Cachexia. Physiological Reviews 89: 381-410, 
2009. 
31.  Winship A, Correia J, Krishnan T, Menkhorst E, Cuman C, Zhang JG, Nicola 
NA, and Dimitriadis E. Blocking Endogenous Leukemia Inhibitory Factor During 
Placental Development in Mice Leads to Abnormal Placentation and Pregnancy Loss. 
Scientific Reports 5: 13237, 2015 
  
	 24 
CURRICULUM VITAE 
		
25 
